Welcome to our dedicated page for CHEMED SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corp CEO Joel L. Wherley reported equity compensation activity tied to performance stock units on February 13, 2026. He acquired 273 shares of capital stock through the exercise of PSUs at an exercise price of $469.56 per share and had 852 shares of capital stock directly owned afterward. The company’s cumulative adjusted earnings per share of $67.67 for the 2023–2025 period exceeded the $66.46 maximum payout threshold, resulting in a PSU payout of 123% of target, or 124.1% including dividend reinvestment. A separate PSU award based on relative total shareholder return for the same period paid out at 0% of target.
Chemed Corporation’s VP & Chief Financial Officer Michael D. Witzeman reported equity compensation activity tied to performance stock units (PSUs). On 02/13/2026, 413 shares of capital stock were issued at $469.56 per share from PSU vesting, with 120 shares withheld to cover taxes, leaving 5,953 shares directly owned.
The PSU vesting was driven by performance from January 1, 2023 through December 31, 2025. Cumulative adjusted EPS of $67.67 exceeded the maximum payout threshold of $66.46, producing an award at 123% of target, or 124.1% including dividend reinvestment. A separate PSU tranche tied to relative total shareholder return over the same period paid out at 0%, including dividends. Witzeman also received a grant of 1,394 new PSUs that can each convert into one share of capital stock based on performance from January 1, 2026 to December 31, 2028, with final performance determined by March 15, 2029.
Chemed Corp director and president/CEO Kevin J. McNamara reported equity compensation activity involving performance stock units and company shares. On February 13, 2026, performance stock units (PSUs) vested and were settled in 2,714 shares of capital stock at $469.56 per share, with 1,192 shares withheld to cover tax obligations.
The vested PSUs tied to cumulative adjusted earnings per share from January 1, 2023 through December 31, 2025, where actual performance of $67.67 exceeded the maximum payout threshold of $66.46, yielding an award of 123% of target, or 124.1% of target including reinvested dividends. A separate PSU tranche based on relative total shareholder return over the same period earned 0% of target, even after dividend reinvestment.
McNamara also received a new grant of 5,114 PSUs that will vest based on performance targets over January 1, 2026 to December 31, 2028, with the performance level to be determined by March 15, 2029 and any earned shares delivered thereafter.
Chemed VP and Chief Legal Officer Brian C. Judkins reported performance stock unit activity and related share movements. On February 13, 2026, 351 shares of capital stock were acquired at $469.56 per share upon PSU vesting, with 102 shares withheld to cover taxes, leaving 2,436 shares directly owned.
Two PSU tranches of 283 units each were exercised, and Judkins then received a new award of 908 performance stock units, bringing his direct PSU holdings to 2,306 units. One PSU program based on cumulative adjusted EPS paid out at 123% of target (124.1% including dividends) after achieving $67.67 versus a $66.46 maximum threshold, while a separate total shareholder return PSU program paid out at 0% of target.
Chemed Corp. director Andrea R. Lindell reported a small change in ownership. On 12/26/2025, Lindell disposed of 463 shares of Chemed capital stock in a transaction coded "G," which indicates a gift. Following this transfer, Lindell beneficially owns 5,539 shares of Chemed stock, held directly. This filing simply updates public records of insider ownership for the company.
Chemed filed a notice of proposed sale under Rule 144 covering 942 shares of its common stock. These shares are planned to be sold through UBS Financial Services Inc. on the NYSE, with an approximate sale date of 12/11/2025 and an aggregate market value of 405,645. The filing notes that 14,164,195 shares of common stock were outstanding, giving context for the size of this planned transaction. The seller acquired the 942 shares in a private transaction from Chemed on 12/01/2025 and paid for them on the same date.
Chemed Corp. insider Kevin J. McNamara, who serves as director, president and CEO, reported a sale of company stock. On 11/24/2025, he sold 2,000 shares of Chemed capital stock in an open market transaction coded as "S" for sale. The weighted average sale price was $437.55 per share, with individual trade prices ranging from $436.13 to $438.53.
After this transaction, McNamara beneficially owns 94,197 shares of Chemed stock in direct form. He has indicated a willingness to provide detailed breakdowns of the number of shares sold at each separate price within the reported range to Chemed, its security holders, or SEC staff upon request.
CHE has a Form 144 notice indicating a planned sale of 2,000 common shares. The shares are to be sold through Raymond James & Associates on or about 11/24/2025 on the NYSE, with an aggregate market value of $876,000. Shares outstanding were 14,110,000; this is a baseline figure, not the amount being sold.
The seller acquired the shares through stock awards from the issuer in 2016. The filing also lists prior sales over the past three months by Kevin J McNamara, including 1,000 common shares for gross proceeds of $460,647 and 2,000 common shares for $922,794, both on 09/26/2025. The signer represents they are not aware of undisclosed material adverse information about the issuer.
Chemed Corp executive vice president reports small share transfer
Chemed Corp executive vice president Spencer S. Lee reported a change in ownership of company stock. On 11/19/2025, Lee disposed of 60 shares of Chemed Corp capital stock in a transaction coded "G," which typically denotes a gift or similar transfer, at a reported price of $0.00 per share. After this transaction, Lee beneficially owns 14,567 shares directly.
Chemed (CHE) reported Q3 2025 results. Service revenues and sales were $624.9 million, up from $606.2 million a year ago. Net income was $64.2 million versus $75.8 million, and diluted EPS was $4.46 compared with $5.00. Segment revenue was $407.7 million at VITAS and $217.2 million at Roto‑Rooter.
For the first nine months, revenue reached $1.89 billion (vs. $1.79 billion) with net income of $188.5 million (vs. $211.7 million). Cash from operations was $254.7 million, supporting $253.5 million of share repurchases year‑to‑date, including $180.8 million in Q3. Cash was $129.8 million, and approximately $404.5 million remained available under the revolving credit facility. The company paid a $0.60 per share dividend in Q3; shares outstanding were 14,164,195 as of September 30, 2025. In VITAS, an Administrative Law Judge largely upheld higher‑level‑of‑care billings; the Medicare Administrative Contractor refunded the previously deposited amount, reducing the overpayment to a de minimis figure. Board repurchase authorization remaining was $301.8 million.